Heers Hendrik, Boegemann Martin, Hegele Axel
Aktuelle Urol. 2019 Feb;50(1):23-31. doi: 10.1055/a-0759-3664. Epub 2019 Feb 7.
We are living in exciting times for urological oncology. The numbers of clinical trials are ever rising, a stream of new substances for tumour therapy is introduced. As it is more challenging than ever to obtain an overview as a clinician, this article aims to summarise the most important news with regard to the 3 most eminent urological tumour entities. Recent data from the most relevant urological and oncological conferences in 2018 on prostate cancer, renal cell carcinoma, and urothelial cancer are reported and their relevance for clinical practice is discussed.
我们正生活在泌尿肿瘤学令人兴奋的时代。临床试验的数量不断增加，一系列用于肿瘤治疗的新物质不断推出。对于临床医生来说，要全面了解情况比以往任何时候都更具挑战性，因此本文旨在总结关于3种最主要泌尿肿瘤实体的最重要消息。报道了2018年最相关的泌尿和肿瘤学会议上有关前列腺癌、肾细胞癌和尿路上皮癌的最新数据，并讨论了它们在临床实践中的相关性。
